Cumberland Pharmaceuticals Inc. (CPIX)

NASDAQ: CPIX · USD

$4.85

-0.10 (-2.0%)· Recorded snapshot

Market cap	72.7M
Revenue (ttm)	44.3M
Net income (ttm)	-10.9M
EPS (ttm)	-$0.74
Shares out	15M
Volume	138,378
Beta	0.04

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 44.3M
Net income (ttm): -10.9M
EPS (ttm): -$0.74
Market cap: 72.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	نگه‌داری

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-14.4

P25 n/aP50 n/aP75 n/a

ROIC-15.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CPIX indicators

Market & fundamental data

Available fields

238

Groups with data

Currency

USD

Showing 238 of 238 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001087294
Company name	Cumberland Pharmaceuticals Inc.
Country	United States
Country code	US
CUSIP number	230770109
Earnings date	2026-11-10
Earnings time	amc
Employees	88
Employees change	-5
Employees growth	-5.38%
Enterprise value	$73.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1999
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2009-08-11
Is primary listing	Yes
Is SPAC	No
ISIN number	US2307701092
Last 10-K release date	2026-03-09
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$72.7M
Market cap category	Micro-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$4.85
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	CPIX
U.S. state	Tennessee
Website	https://www.cumberlandpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-15.25%
EV/EBITDA	68.4x
EV/FCF	109.69x
EV/Sales	1.69x
FCF / EV yield	0.91%
FCF yield	0.92%
Industry forward P/E	13.86x
Industry P/E	173.47x
P/(FCF - SBC) ratio	301.77x
P/(OCF - SBC) ratio	240.93x
P/B ratio	4.25x
P/FCF ratio	108.45x
P/OCF ratio	99.42x
P/S ratio	1.67x
Price / tangible book value	4.26x
Price/EBITDA ratio	67.63x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-6.87%
EBITDA margin	2.48%
FCF margin	1.54%
Gross margin	84.95%
Operating margin	-6.87%
Pretax margin	-7.19%
Profit margin	-24.64%
Profit per employee	$-124,074
Revenue per employee	$503,458
ROA	-2.91%
ROA (5Y)	-4.23%
ROCE	-10.99%
ROE	-14.39%
ROE (5Y)	-16.67%
ROIC	-15.88%
ROIC (5Y)	-18.41%
SBC / revenue	0.99%
Tax / revenue	0.08%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
FCF growth	-90.27%
FCF growth 3Y	-59.07%
FCF growth 5Y	-35.38%
Gross profit growth	124.44%
Gross profit growth (Q)	-56.29%
Gross profit growth 3Y	4.48%
Gross profit growth 5Y	4.27%
Net income growth years	1
OCF growth	-89.53%
OCF growth 10Y	-5.14%
OCF growth 3Y	-58.03%
OCF growth 5Y	-34.52%
Revenue growth	120.76%
Revenue growth (Q)	-56.29%
Revenue growth (QoQ)	1.59%
Revenue growth 10Y	3.61%
Revenue growth 3Y	2.91%
Revenue growth 5Y	2.53%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-62,070
Depreciation and amortization	$4.1M
EBIT	$-3M
EBITDA	$1.1M
EPS	$-0.74
FCF per share	$0.05
Financing cash flow	$-7.2M
Free cash flow	$683,899
Free cash flow minus SBC	$245,769
Gross profit	$37.6M
Income taxes	$36,656
Investing cash flow	$-5.8M
Net borrowing	$-5.2M
Net cash flow	$-12.2M
Net income	$-10.9M
Operating cash flow minus SBC	$307,839
Operating income	$-3M
Revenue	$44.3M
Stock-based compensation	$438,130

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.48
Book value per share	$1.16
Debt / EBITDA	1.42
Debt / equity	0.28
Debt / FCF	6.89
Interest coverage	-6.18
Long-term assets	$29.2M
Long-term liabilities	$10.6M
Net cash (debt)	$-851,782
Net cash / market cap	-1.15%
Net debt / EBITDA	0.78
Net debt / equity	0.05
Net debt / FCF	1.25
Piotroski F-Score	4
Property, plant and equipment	$7.5M
Shareholders' equity	$17.1M
Tangible book value	$17.4M
Tangible book value per share	$1.16
Total assets	$62.9M
Total cash	$3.9M
Total debt	$4.7M
Total liabilities	$45.8M
WACC	4.68%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.68
Current assets	$33.6M
Current liabilities	$35.2M
Current ratio	0.96
Inventory turnover	4.1
Net working capital	$-4.9M
Quick ratio	0.49
Working capital	$-1.6M
Working capital turnover	15.6

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.64%
Dividend growth years	0
Dividend payment date	2026-07-31
Dividend payment years	1
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$1.50
Shareholder yield	-2.64%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	1.89%
10Y return CAGR	2.77%
10Y total return	31.4%
150-day SMA	$6.10
15Y price change	-15.51%
15Y return CAGR	0.57%
15Y total return	8.96%
1D price change	-2.02%
1M price change	-36.27%
1M total return	-36.27%
1W price change	-40.64%
1W total return	-40.64%
1Y price change	52.04%
1Y return CAGR	96.15%
1Y total return	96.06%
20-day SMA	$7.02
200-day SMA	$5.52
3M price change	-31.01%
3M total return	-11.03%
3Y price change	138.33%
3Y return CAGR	45.38%
3Y total return	207.34%
50-day SMA	$7.25
50-day SMA vs 200-day SMA	50over200
52-week high	$9.28
52-week high date	2026-08-26
52-week low	$1.85
52-week low date	2025-11-18
5Y price change	88.72%
5Y return CAGR	19.47%
5Y total return	143.36%
6M price change	15.75%
6M total return	49.27%
All-time high	$17.75
All-time high date	2009-08-11
All-time low	$1.04
All-time low date	2024-11-25
Average true range (ATR)	$0.84
Average volume	105.2K
Beta (1Y)	1.77
Beta (2Y)	0.06
Beta (5Y)	0.04
Change from 52-week high	-47.74%
Change from 52-week low	162.16%
Change from all-time high	-72.68%
Change from all-time low	366.35%
Change from open	-2.22%
Day's gap	0.2%
Dollar volume	$671,133
High price	$5.11
Low price	$4.85
Monthly RSI	52.36
Open price	$4.96
Position in 52-week range	0%
Premarket change	-2.63%
Premarket close	$4.95
Premarket price	$4.82
Previous close	$4.95
Price vs 150-day SMA	-20.44%
Price vs 20-day SMA	-30.89%
Price vs 200-day SMA	-12.17%
Price vs 50-day SMA	-33.06%
Relative volume	1.36
RSI	34.36
Sharpe ratio	1.16
Sharpe ratio (3Y)	0.81
Sharpe ratio (5Y)	0.59
Sortino ratio	1.81
Sortino ratio (3Y)	1.59
Sortino ratio (5Y)	1.28
Volume	138.4K
Weekly RSI	42.47
YTD price change	21.86%
YTD total return	57.15%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	8.7M
Float percentage	58.06%
Shares change (QoQ)	0.14%
Shares change (YoY)	2.64%
Shares held by insiders	41.94%
Shares held by institutions	16.63%
Shares outstanding	15M
Short % of float	4.01%
Short % of shares	2.33%
Short ratio	7.5 days

Deeper analysis on CPIX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CPIX report

Is a complete CPIX research report available?

No complete published report is available for Cumberland Pharmaceuticals Inc. (CPIX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cumberland Pharmaceuticals Inc. (CPIX)

Price

Financial snapshot

Fair-value bridge

Latest news · CPIX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CPIX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CPIX

Frequently asked questions